Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate [alendronic acid] in Postmenopausal Women With Low Bone Mineral Density.

Trial Profile

A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate [alendronic acid] in Postmenopausal Women With Low Bone Mineral Density.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DAPS
  • Sponsors Amgen
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jan 2012 Final results published in Osteoporosis International.
    • 23 Mar 2011 Results have been presented at ECCEO11-IOF according to an Amgen media release; results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top